Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
September 30, 2026 19.99M
June 30, 2026 -2.411M
March 31, 2026 -2.077B
December 31, 2025 322.35M
September 30, 2025 -6.737M
June 30, 2025 -29.21M
March 31, 2025 9.102M
December 31, 2024 -13.88M
September 30, 2024 -109.33M
June 30, 2024 51.85M
March 31, 2024 -39.95M
December 31, 2023 -20.98M
September 30, 2023 -119.36M
June 30, 2023 120.85M
March 31, 2023 72.85M
December 31, 2022 27.74M
September 30, 2022 8.898M
June 30, 2022 -40.54M
March 31, 2022 -60.64M
December 31, 2021 -0.742M
September 30, 2021 -31.71M
June 30, 2021 3.977M
March 31, 2021 -37.73M
December 31, 2020 -35.10M
September 30, 2020 -8.227M
Date Value
June 30, 2020 14.35M
March 31, 2020 17.49M
December 31, 2019 -101.47M
September 30, 2019 31.59M
June 30, 2019 -7.253M
March 31, 2019 -64.70M
December 31, 2018 -7.803M
September 30, 2018 26.15M
June 30, 2018 -65.88M
March 31, 2018 25.34M
December 31, 2017 -14.19M
September 30, 2017 -13.60M
June 30, 2017 -6.021M
March 31, 2017 15.46M
December 31, 2016 -20.88M
September 30, 2016 46.99M
June 30, 2016 28.44M
March 31, 2016 72.69M
December 31, 2015 -42.22M
September 30, 2015 30.51M
June 30, 2015 -2.989M
March 31, 2015 -28.79M
December 31, 2014 46.13M
September 30, 2014 -63.69M
June 30, 2014 26.84M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Amarin Corp. Plc 4.556M
Prothena Corp. Plc -0.0686M
Cue Biopharma, Inc. 0.00
ACADIA Pharmaceuticals, Inc. -86.15M
Alnylam Pharmaceuticals, Inc. -311.74M